GTC
Ghost Tree Capital Portfolio holdings
AUM
$276M
This Quarter Return
+12.2%
1 Year Return
+49.13%
3 Year Return
+198.45%
5 Year Return
+1,783.74%
10 Year Return
+9,775.89%
AUM
$276M
AUM Growth
+$276M
(-4%)
Cap. Flow
-$42.3M
Cap. Flow
% of AUM
-15.35%
Top 10 Holdings %
Top 10 Hldgs %
40.38%
Holding
70
New
9
Increased
16
Reduced
22
Closed
18
Top Buys
| 1 |
Novo Nordisk
NVO
|
$13.1M |
| 2 |
BPMC
Blueprint Medicines
BPMC
|
$9.25M |
| 3 |
Sarepta Therapeutics
SRPT
|
$8.12M |
| 4 |
Janux Therapeutics
JANX
|
$6.36M |
| 5 |
Edgewise Therapeutics
EWTX
|
$5.2M |
Top Sells
| 1 |
Biohaven
BHVN
|
$17M |
| 2 |
Viridian Therapeutics
VRDN
|
$11.7M |
| 3 |
MoonLake Immunotherapeutics
MLTX
|
$8.65M |
| 4 |
Vaxcyte
PCVX
|
$8M |
| 5 |
Soleno Therapeutics
SLNO
|
$7.57M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Taysha Gene Therapies
TSHA
$797M
| $4.32M | 1.31% |
2,150,000
+900,000
| +72% | +$1.81M |
|
27
Rhythm Pharmaceuticals
RYTM
$6.85B
| $4.13M | 1.25% |
78,842
-38,546
| -33% | -$2.02M |
|
28
Annexon
ANNX
$226M
| $3.85M | 1.16% |
650,000
+340,000
| +110% | +$2.01M |
|
29
Korro Bio
KRRO
$217M
| $3.68M | 1.11% |
110,000
+10,000
| +10% | +$334K |
|
30
Dyne Therapeutics
DYN
$1.92B
| $3.59M | 1.09% |
+100,000
| New | +$3.59M |
|
31
Arvinas
ARVN
$568M
| $3.57M | 1.08% |
145,000
+70,000
| +93% | +$1.72M |
|
32
Corbus Pharmaceuticals
CRBP
$115M
| $3.3M | 1% |
160,000
-15,000
| -9% | -$309K |
|
|
BBOT
33
BridgeBio Oncology Therapeutics, Inc. Common Stock
BBOT
$708M
| $3.13M | 0.95% |
300,000
| – | – |
|
34
Nuvation Bio
NUVB
$1.02B
| $3.09M | 0.93% |
1,350,000
+200,000
| +17% | +$458K |
|
35
Savara
SVRA
$567M
| $3.07M | 0.93% |
725,000
-325,876
| -31% | -$1.38M |
|
36
Tenaya Therapeutics
TNYA
$184M
| $2.9M | 0.87% |
1,500,000
+150,000
| +11% | +$290K |
|
37
Regenxbio
RGNX
$451M
| $2.78M | 0.84% |
265,000
+95,000
| +56% | +$997K |
|
38
Corvus Pharmaceuticals
CRVS
$428M
| $2.64M | 0.8% |
+500,000
| New | +$2.64M |
|
39
Absci
ABSI
$357M
| $2.1M | 0.63% |
+550,000
| New | +$2.1M |
|
40
Neurogene
NGNE
$264M
| $2.1M | 0.63% |
50,000
-20,000
| -29% | -$839K |
|
41
Capricor Therapeutics
CAPR
$287M
| $1.9M | 0.57% |
+125,000
| New | +$1.9M |
|
42
Apellis Pharmaceuticals
APLS
$3.48B
| $1.87M | 0.57% |
65,000
-70,000
| -52% | -$2.02M |
|
43
Summit Therapeutics
SMMT
$17.6B
| $1.86M | 0.56% |
+85,000
| New | +$1.86M |
|
44
Spyre Therapeutics
SYRE
$996M
| $1.76M | 0.53% |
60,000
-190,237
| -76% | -$5.59M |
|
|
45
Viridian Therapeutics
VRDN
$1.5B
| $1.71M | 0.52% |
75,000
-512,708
| -87% | -$11.7M |
|
46
ProQR Therapeutics
PRQR
$237M
| $1.62M | 0.49% |
887,700
-12,300
| -1% | -$22.4K |
|
|
ATYR
47
aTyr Pharma
ATYR
$527M
| $1.41M | 0.43% |
800,000
| – | – |
|
48
Larimar Therapeutics
LRMR
$310M
| $1.31M | 0.4% |
+200,000
| New | +$1.31M |
|
49
enGene Holdings
ENGN
$236M
| $1.06M | 0.32% |
160,898
-259,433
| -62% | -$1.71M |
|
50
Amylyx Pharmaceuticals
AMLX
$836M
| $1.05M | 0.32% |
+325,000
| New | +$1.05M |
|